drugset

drugset / Trial / NCT03183674

Oxytocin in Spectrum Autism Disorders

NCT03183674 ↗

Phase 1 Completed 80 enrolled University of Sao Paulo General Hospital

RandomizedCrossoverQuadruple-blindOther

Summary

Observe effects of oxytocin on individuals with autism spectrum disorder

Timeline

Start: 2016-07-15
Primary completion: 2017-07-20
Completion: 2018-05-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxytocin	Peptide	0.4 iu/kg	Intranasal

Indications